Testing
IHC and ISH
IHC measures HER2 protein. ISH evaluates gene amplification. Equivocal results require careful interpretation.
Breast Cancer Subtype · HER2-Positive
HER2-Positive Breast Cancer Treatment With Integrative Support
HER2-positive breast cancer can occur at any stage. Confirming HER2 biology and understanding prior treatment are essential because HER2-directed options and sequencing continue to evolve.
Answer first: HER2-positive treatment is selected by stage, tumor size, lymph nodes, hormone-receptor status, prior HER2 therapy, response and recurrence timing. Integrative care can be organized around strength, symptoms, immune health and quality of life.
Cancer Consultation
Speak With Our Cancer Patient Care Team
Tell us where you are in your cancer journey. Our Patient Care Team can answer questions and help determine the next step.
*
Required fields
Prefer to speak with someone now?
1-800-923-7878
✓
Stage 4 & advanced cancer patients welcome
✓
Out-of-state & international patients welcome
✓
Questions before scheduling are welcome
Understand the result
HER2-positive is a subtype—not a stage.
Hormones
ER and PR still matter
Some tumors are both HER2-positive and hormone receptor-positive, creating more than one treatment pathway.
Change over time
Retesting can matter
A recurrent or metastatic tumor may not have the same biomarker pattern as the original breast tumor.
HER2 treatment protocols
Examples patients may encounter in an oncology plan.
Early and locally advanced disease
Protocols may combine chemotherapy with trastuzumab (Herceptin) and pertuzumab (Perjeta), sometimes before surgery. Paclitaxel (Taxol), docetaxel (Taxotere), carboplatin (Paraplatin), cyclophosphamide (Cytoxan) and other agents may appear in stage- and risk-specific regimens.
Residual disease and recurrence
Ado-trastuzumab emtansine (Kadcyla), fam-trastuzumab deruxtecan-nxki (Enhertu), tucatinib (Tukysa), capecitabine (Xeloda), neratinib (Nerlynx) and other HER2-directed strategies may be considered according to prior therapy and the current setting.
Metastatic disease
Treatment sequencing is individualized and changes as approvals and evidence develop. Brain metastases, hormone-receptor status, cardiac function and prior response can affect the choice.
Testing and monitoring
Follow the person as carefully as the tumor.
- Pathology confirmation and complete HER2 testing report.
- Cardiac monitoring when a HER2-directed medicine can affect heart function.
- Blood counts, liver and kidney measures appropriate to the regimen.
- Evaluation of respiratory symptoms with antibody-drug conjugates when clinically relevant.
- Repeat imaging, tumor markers when useful, and reassessment of treatment goals.
Integrative HER2 support
Build resilience around a complex treatment pathway.
Infusions
IV vitamin C and glutathione
Sunridge may evaluate infusion-based support in the context of the complete medication schedule, symptoms, organ function and goals.
Natural compounds
Mistletoe and polyphenols
Mistletoe, curcumin, resveratrol, silymarin and EGCG have different levels of human and preclinical evidence and are considered individually.
Immune assessment
NK cells and immune context
Selected immune measurements may add context to the overall assessment; they do not replace HER2 pathology or standard response evaluation.
Research and next steps
Use current sources and the complete case.
Primary references include the NCI Breast Cancer Treatment PDQ, NCI targeted-therapy guide and current FDA prescribing information.
Questions patients ask
HER2-positive breast cancer FAQs
Is HER2-positive breast cancer the same as Stage 4?
No. HER2 describes tumor biology; stage describes extent of disease.
Can HER2 status change?
Yes. When disease recurs or spreads, repeat tissue or liquid-biopsy evaluation may be appropriate.
Can natural therapies be included during HER2 treatment?
A physician can review the complete regimen, laboratory findings and goals to determine which integrative strategies fit the individual plan.
A closer look
How this topic fits the complete breast-cancer plan.
HER2-directed care often involves several phases: treatment before surgery, surgery, treatment after surgery, surveillance and—when necessary—treatment for recurrent or metastatic disease. The meaning of each option depends on what came before it. A patient with newly diagnosed early disease has a different question from someone whose cancer has progressed after trastuzumab, pertuzumab or an antibody-drug conjugate.
For an integrative review, timing matters. Symptoms, heart function, liver tests, blood counts, lung symptoms, neuropathy and gastrointestinal effects may influence what support is most useful. Sunridge reviews the entire HER2 schedule before recommending infusions, botanicals or other therapies and identifies concrete goals such as energy, appetite, sleep, mobility, treatment tolerance and recovery.
Prepare for a Sunridge review
The right records make the first conversation more useful.
Before contacting the Patient Care Team, gather the original and current HER2 reports, treatment dates, cardiac studies, imaging, laboratory results and current symptoms. A concise one-page chronology is often helpful: diagnosis date, stage, major test results, treatments received, response, side effects and the questions that matter most now.
Step 1
Send the records
The team can explain which reports and images are needed before a physician review.
Step 2
Define the priorities
List the treatment, symptom, recovery and quality-of-life questions you want the consultation to address.
Step 3
Plan the visit
Out-of-state and international patients can discuss timing, Scottsdale travel and which services require an in-person appointment.
Continue exploring
Explore Sunridge integrative therapies
Learn how these physician-directed therapies are evaluated within a personalized cancer-care program.
A personalized next step
Bring the complete breast-cancer story to the conversation.
Our Patient Care Team can explain which records to send, how a physician review works and what to expect when traveling to Scottsdale.
Request a consultationCall 1-800-923-7878This page is educational and does not provide a diagnosis or individualized treatment recommendation. Medication and integrative-treatment decisions require review of the complete case by qualified clinicians. Content reviewed August 2026.